|
1
|
Kesmezacar H, Oğüt T, Bilgili MG, Gökay S
and Tenekecioğlu Y: Treatment of intertrochanteric femur fractures
in elderly patients: internal fixation or hemiarthroplasty. Acta
Orthop Traumatol Turc. 39:287–294. 2005.(In Turkish).
|
|
2
|
Angelini M, McKee MD, Waddell JP,
Haidukewych G and Schemitsch EH: Salvage of failed hip fracture
fixation. J Orthop Trauma. 23:471–478. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Talmo CT and Bono JV: Treatment of
intertrochanteric nonunion of the proximal femur using the S-ROM
prosthesis. Orthopedics. 31:1252008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dhammi I, Jain A, Singh A, Rehan-Ul-Haq,
Mishra P and Jain S: Primary nonunion of intertrochanteric
fractures of femur: an analysis of results of valgization and bone
grafting. Indian J Orthop. 45:514–519. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Looker AC, Bauer DC, Chesnut CH 3rd,
Gundberg CM, Hochberg MC, Klee G, Kleerekoper M, Watts NB and Bell
NH: Clinical use of biochemical markers of bone remodeling: current
status and future directions. Osteoporos Int. 11:467–480. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kurban S and Mehmetoglu I:
Osteoprotegerin, RANK and RANK ligand. Turk J Biochem. 34:178–184.
2007.
|
|
7
|
Stejskal D, Bartek J, Pastorková R,
Růzicka V, Oral I and Horalík D: Osteoprotegerin, RANK, RANKL.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 145:61–64.
2001. View Article : Google Scholar
|
|
8
|
Khosla S: Minireview: the OPG/RANKL/RANK
system. Endocrinology. 142:5050–5055. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kostenuik PJ and Shalhoub V:
Osteoprotegerin: a physiological and pharmacological inhibitor of
bone resorption. Curr Pharm Des. 7:613–635. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bucay N, Sarosi I, Dunstan CR, Morony S,
Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ
and Simonet WS: Osteoprotegerin-deficient mice develop early onset
osteporosis and arterial calcification. Genes Dev. 12:1260–1268.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gravallese EM, Manning C, Tsay A, Naito A,
Pan C, Amento E and Goldring SR: Synovial tissue in rheumatoid
arthritis is a source of osteoclast differentiation factor.
Arthritis Rheum. 43:250–258. 2004.PubMed/NCBI
|
|
12
|
Hafbauer LC and Schoppet M: Clinical
implications of the osteoprotegerin/RANKL/RANK system for bone and
vascular diseases. JAMA. 292:490–495. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Masi L, Simonini G, Giani T, Del Monte F,
Giani T, Cimaz R, Vierucci S, Brandi ML and Falcini F:
Osteoprotegerin (OPG)/RANKL system in juvenile idiopathic arthitis:
is there a potential modulating role for OPG/RANKL in bone injury?
J Rheumatol. 31:986–991. 2004.PubMed/NCBI
|
|
14
|
Blaır JM, Zheng Y and Dunstan CR: RANK
ligand. Int J Biochem Cell Biol. 39:1077–1081. 2007.
|
|
15
|
Chamoux E, Houde N, L’Eriger K and Roux S:
Osteoprotegerin decreases human osteoclast apoptosis by inhibiting
the TRAIL pathway. J Cell Physiol. 216:536–542. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Boyce BF and Xing L: Function of
RANKL/RANK/OPG in bone modeling end remodeling. Arch Biochem
Biophys. 473:139–146. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lacey DL, Timms E, Tan HL, et al:
Osteoprotegerin ligand is a cytokine that regulates osteoclast
differentiation and activation. Cell. 93:165–176. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Simonet WS, Lacey DL, Dunstan CR, et al:
Osteoprotegerin: a novel secreted protein involved in the
regulation of bone density. Cell. 89:309–319. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Son A, Kim MS, Jo H, Byun HM and Shin DM:
Effects of inositol 1,4,5-triphosphate on osteoclast
differentiation in RANKL-induced osteoclastogenesis. Korean J
Physiol Pharmacol. 16:31–36. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schett G, Kiechl S, Redlich K,
Oberhollenzer F, Weger S, Egger G, Mayr A, Jocher J, Xu Q,
Pietschmann P, Teitelbaum S, Smolen J and Willeit J: Soluble RANKL
and risk of non-traumatic fracture. JAMA. 291:1108–1113. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Abdallah BM, Stilgren LS, Nissen N, Kassem
M, Jørgensen HR and Abrahamsen B: Increased RANKL/OPG mRNA ratio in
iliac bone biopsies from women with hip fractures. Calcif Tissue
Int. 76:90–97. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yasuda H, Shima N, Nakagawa N, Yamaguchi
K, Kinosaki M, Goto M, Mochizuki SI, Tsuda E, Morinaga T, Udagawa
N, Takahashi N, Suda T and Higashio K: A novel molecular mechanism
modulating osteoclast differentiation and function. Bone.
25:109–113. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wasilewska A, Rybi-Szuminska A and
Zoch-Zwierz W: Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG
ratio in nephrotic children. Pediatr Nephrol. 25:2067–2075. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hofbauer LC, Khosla S, Dunstan CR, Lacey
DL, Boyle WJ and Riggs BL: The roles of osteoprotegerin and
osteoprotegerin ligand in the paracrine regulation of bone
resorption. J Bone Miner Res. 15:2–12. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Coetzee M and Kruger MC:
Osteoprotegerin-receptor activator of nuclear factor-kappaB ligand
ratio: a new approach to osteoporosis treatment? South Med J.
97:506–511. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tsangari H, Findlay DM, Kuliwaba JS,
Atkins GJ and Fazzalari NL: Increased expression of IL-6 and RANK
mRNA in human trabecular bone from fragility fracture of the
femoral neck. Bone. 35:334–342. 2004. View Article : Google Scholar : PubMed/NCBI
|
